




Instance: composition-en-8fbc69d3de50a0eced9467159e7edfb2
InstanceOf: CompositionUvEpi
Title: "Composition for colobreathe Package Leaflet"
Description:  "Composition for colobreathe Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6f08bfaab2005a985ea433c3e1d4d35c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - colobreathe"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Colobreathe is and what it is used for </li>
<li>What you need to know before you use Colobreathe </li>
<li>How to use Colobreathe </li>
<li>Possible side effects </li>
<li>How to store Colobreathe </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What colobreathe is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What colobreathe is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Colobreathe contains colistimethate sodium, a type of antibiotic called a polymyxin.  </p>
<p>Colobreathe is used to control persistent lung infections caused by the bacterium Pseudomonas 
aeruginosa in adult patients and children aged 6 years and older with cystic fibrosis. Pseudomonas 
aeruginosa is a very common bacterium that infects nearly all cystic fibrosis patients at some time 
during their lives. Some people will get this infection whilst very young but for others it will be much 
later. If this infection is not properly controlled it will cause damage to the lungs.  </p>
<p>How it works 
Colobreathe works by destroying the bacterial cell membrane, having a lethal effect on them.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take colobreathe"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take colobreathe"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Colobreathe 
  if you/your child are allergic to colistimethate sodium, colistin sulphate or polymyxins. </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before using Colobreathe. </p>
<p>Tell your doctor if you/your child has ever had any of the following conditions 
  have reacted badly to inhaled dry powder medicines previously unless this has already been 
discussed with your doctor. 
  already have a muscle condition known as myasthenia gravis or the inherited condition, 
porphyria 
  blood in your sputum (the substance you cough up) </p>
<p>After each inhalation of Colobreathe, the mouth should be rinsed with water. The rinse should not be 
swallowed. Rinsing may reduce the risk of developing oral fungal super-infection during treatment 
and may also reduce the unpleasant taste associated with colistimethate sodium. 
When you/your child start using Colobreathe, you/your child may find they have cough, 
breathlessness, tightness of chest or wheezing. The number of these side-effects may reduce as you 
continue to use the inhaler or your doctor may prescribe a bronchodilator to use before or after taking 
Colobreathe. If any of these effects become a problem, please contact your doctor who may change 
your treatment. </p>
<p>If you/your child has any problems with your kidneys or nerves, care should be taken when 
administering Colobreathe but your doctor should be aware of this. </p>
<p>If you/your child needs to have other forms of colistimethate either by injection or nebulisation 
caution should be used but your doctor should be aware of this. </p>
<p>Children 
Do not give Colobreathe to children under the age of 6 years as it is not suitable for them. </p>
<p>Other medicines and Colobreathe 
Tell your doctor if you/your child are taking, have recently taken or might take any other medicines, 
and in particular: </p>
<ul>
<li>if you/your child are taking aminoglycoside antibiotics used to treat infections caution must be 
taken; </li>
<li>if you/your child suffer from myasthenia gravis and are taking macrolide type antibiotics such 
as azithromycin and clarithromycin, or fluoroquinolones such as norfloxacin and 
ciprofloxacin. Taking these at the same time as Colobreathe may cause problems with muscle 
weakness; </li>
<li>if you/your child are taking colistimethate by injection or nebulisation caution must be taken; </li>
<li>if you/your child need to have a general anaesthetic caution must be taken. </li>
</ul>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before using this medicine. </p>
<p>There is no information about the safety of Colobreathe in pregnant women. Your doctor should 
advise you before using Colobreathe whether the benefits of the medicine exceed the risks. </p>
<p>Colistimethate sodium may be secreted in the breast milk. Please discuss the use of Colobreathe with 
your doctor. </p>
<p>Driving and using machines 
It is possible while using Colobreathe that you may experience dizziness, confusion or have problems 
with your sight. Do not drive or use any machines until the symptoms have gone away. </p>
<p>Colobreathe contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take colobreathe"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take colobreathe"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always use this medicine exactly as your doctor has told you. Check with your doctor if you/your 
child are not sure. </p>
<p>The first dose should be given under medical supervision. </p>
<p>The recommended dose is 
Adults and children 6 years of age and older </p>
<p>The contents of one Colobreathe capsule should be inhaled twice a day using the Turbospin 
inhaler. 
  There should be a 12 hour gap between doses. </p>
<p>The order in which other treatments should be taken or carried out 
If you/your child are taking other treatments for cystic fibrosis you/your child should take them in the 
following order: 
* Inhaled bronchodilators 
* Chest physiotherapy<br />
* Other inhaled medicines 
* Then Colobreathe  </p>
<p>You/your child should confirm the order of your treatments with your doctor. </p>
<p>Method of administration </p>
<p>Colobreathe is inhaled into the lungs as a powder from the capsule using the hand-held inhaler called 
the Turbospin. Colobreathe can only be administered using this device. </p>
<p>Do not swallow Colobreathe capsules.  </p>
<p>To inhale Colobreathe from the capsule through the Turbospin inhaler follow the procedure described 
below. Your doctor, pharmacist or nurse should show you/your child how to inhale the medicine when 
you/your child first start treatment: </p>
<p>Taking Colobreathe using the Turbospin inhaler </p>
<p>Preparing the Turbospin </p>
<ol>
<li>
<p>Remove the cap. It comes away with a gentle pull. </p>
</li>
<li>
<p>Unscrew the mouthpiece, exposing the chamber of the Turbospin inhaler. </p>
</li>
<li>
<p>Remove a single capsule from the blister. Once you have removed the capsule it must be used 
immediately. </p>
</li>
<li>
<p>Gently insert the capsule into the chamber with the widest end first. No force is required.  </p>
</li>
<li>
<p>Now replace the mouthpiece by screwing it back into place. </p>
</li>
</ol>
<p>Piercing the capsule and inhaling the medicine </p>
<ol>
<li>To pierce the capsule: </li>
<li>Hold the inhaler with the mouthpiece upright, gently push the piston upwards until the 
visible line is reached   you will feel resistance at this point and this will lock the capsule 
in place ready for piercing. Hold that position before continuing to follow through with 
the piercing. </li>
<li>Now, with the capsule locked in place, continue pushing the piston as far as it will go and 
then release. </li>
<li>The capsule is now pierced and the contents can be inhaled. </li>
<li>
<p>Do not pierce the capsule more than once. You may see a small amount of powder 
released from the capsule chamber after the capsule is pierced, this is normal. </p>
</li>
<li>
<p>Breathe out slowly. Place the mouthpiece between your lips and teeth. Ensure there is a seal 
between your lips and the mouthpiece. Take care not to cover the air slits with your fingers or 
mouth during inhalation.  </p>
</li>
<li>Then, breathe in slowly and deeply through your mouth at a rate sufficient for you to hear or 
feel the capsule spinning.  </li>
<li>Remove the Turbospin inhaler from your mouth and hold your breath for about 10 seconds or 
for as long as is comfortable, then breathe out slowly. </li>
<li>If you do not hear the capsule spinning, the capsule may be stuck in the compartment. If this 
occurs, you can loosen the capsule by gently tapping the chamber of the inhaler. Do not try to 
loosen the capsule by repeatedly pressing the piston. If the capsule cannot be loosened and the 
powder cannot be inhaled, dispose of the broken capsule and any powder remaining in it and 
use another. </li>
<li>Inhale the medicine again by repeating Steps 7 and 8 to ensure you have emptied the capsule. </li>
<li>You can check whether the capsule is empty by unscrewing the mouthpiece and checking the 
capsule. If it is not empty, repeat steps 7, 8 and 9 until you have inhaled all of the contents.  </li>
<li>Once all the contents have been inhaled, rinse your mouth out well with water and spit out. </li>
</ol>
<p>Removing the empty capsule from the Turbospin </p>
<ol>
<li>When the capsule is empty, unscrew the mouthpiece, then remove and discard the empty 
capsule. </li>
</ol>
<p>Additional information  </p>
<p>As you breathe in slowly, you suck air through the body of the Turbospin inhaler into the capsule 
chamber. The tiny particles of medication in the capsule are picked up by the airflow and carried down 
your airway into your lungs. </p>
<p>Occasionally, very small pieces of the capsule shell can get into your mouth or airways.<br />
<em> If this happens, you may be able to feel these pieces on your tongue or in your airways.<br />
</em> The capsule shell is made of gelatin, which is harmless to humans if swallowed or inhaled. 
* The chances of the capsule breaking into pieces are increased if the capsule is pierced more than 
once during Step 6. Cleaning the Turbospin device </p>
<p>Clean the Turbospin inhaler after each dose using the following procedure: 
1. Deeply press the piston a few times whilst keeping the chamber turned upside down. 
2. Clean the chamber using a tissue or cotton bud. Do not use water. 
3. Screw the mouthpiece firmly back into place, put the cap back on and the inhaler is ready to 
be used for your next dose. </p>
<p>If you/your child use more Colobreathe than you/your child should, or have accidentally 
swallowed the capsule, contact your doctor immediately for advice. </p>
<p>If you/your child forget to use Colobreathe </p>
<p>If you/your child forget to take a dose of Colobreathe then you/your child should take your missed 
dose as soon as you/your child remember. You/your child must not take 2 doses within 12 hours. 
Carry on from there as instructed. </p>
<p>If you/your child stop using Colobreathe </p>
<p>Do not stop your treatment early unless your doctor says you can. Your doctor will decide how long 
you/your child s treatment should last. </p>
<p>If you/your child have any further questions on the use of this medicine, ask your doctor. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines this medicine can cause side effects, although not everyone gets them. </p>
<p>Allergic reactions 
An allergic reaction with Colobreathe is possible (typically serious allergic reactions may cause 
rashes, swelling of the face, tongue and neck, inability to breathe due to narrowing of the airways and 
loss of consciousness). If you/your child experience signs of an allergic reaction you should seek 
urgent medical attention. </p>
<p>Other possible side effects </p>
<p>You/your child may get an unpleasant taste in your mouth after inhaling Colobreathe.  </p>
<p>Very common: may affect more than 1 in 10 people 
* Difficulty in breathing 
* Cough, throat irritation<br />
* Hoarse or weak, or even loss of the voice 
* Unpleasant taste </p>
<p>Common: may affect up to 1 in 10 people 
* Headache 
* Ringing or buzzing noises in the ear, problems with balance<br />
* Coughing up blood, wheezing, chest discomfort, asthma, productive cough (a cough 
which brings up mucus), infection of the lungs, lung crackles (your doctor would hear this 
when listening to your lungs using a stethoscope) 
* Vomiting, nausea 
* Changes in how your lungs function (found by testing) 
* Joint pains 
* Lack of energy, tiredness 
* Raised temperature </p>
<p>Uncommon: may affect up to 1 in 100 people 
* Allergic (hypersensitivity) reactions, the signs may include rash and itching 
* Weight fluctuations, decreased appetite<br />
* Anxiety 
* Fits 
* Sleepiness 
* Blockage in the ears 
* Chest pain 
* Shortness of breath 
* Nose bleeds, catarrh (mucus in your nose, which may make you feel blocked up), 
coughing up thick green mucus, pain in the throat and sinuses 
* Unusual noises in the chest (your doctor would hear this when listening to your lungs with 
a stethoscope) 
* Diarrhoea, wind 
* Excessive production of saliva 
* Toothache 
* Protein in the urine (found by testing) 
* Thirst </p>
<p>The above side effects have been seen in people of all ages with similar frequency. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store colobreathe"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store colobreathe"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.  </p>
<p>Do not use this medicine after the expiry date, which is stated on the outer carton and blister after 
EXP. The expiry date refers to the last date of that month. </p>
<p>Do not store Colobreathe above 25oC. </p>
<p>Store in the original package until immediately before use in order to protect from moisture. </p>
<p>If you/your child accidentally peel back the foil, and any capsules become exposed, please discard 
these capsules. </p>
<p>Discard the Turbospin inhaler after the completion of a treatment pack. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Colobreathe contains 
The active substance is colistimethate sodium. Each capsule contains 1,662,500 IU (approximately 
equivalent to 125 mg) colistimethate sodium. </p>
<p>The other ingredients are: 
Capsule Shell 
Gelatin 
polyethylene glycol 
sodium lauryl sulfate 
purified water </p>
<p>What Colobreathe looks like and contents of the pack 
Colobreathe inhalation powder, hard capsule (inhalation powder) is supplied as small, hard, 
transparent gelatin capsules containing a fine white powder.  </p>
<p>The Turbospin is an inspiratory flow driven dry powder inhaler made of polypropylene and stainless 
steel. </p>
<p>The capsules are packed in blister packs supplied in cartons containing: </p>
<ul>
<li>56 hard capsules and one Turbospin powder inhaler device sufficient for 4 weeks use. </li>
<li>8 hard capsules and one Turbospin inhaler device sufficient for 4 days use. </li>
</ul>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Teva B.V. 
Swensweg 5 
2031 GA Haarlem 
The Netherlands </p>
<p>Manufacturer </p>
<p>Teva Pharmaceuticals Europe BV 
Swensweg 5 
2031 GA Haarlem 
The Netherlands </p>
<p>Millmount Healthcare Limited 
Block 7, City North Business Campus 
Stamullen 
Co Meath 
K32 YDIreland </p>
<p>Merckle GmbH 
Ludwig-Merckle-Str-3 
89143 Blaubeuren 
Germany </p>
<p>Laboratorios Liconsa, S.A. 
Avda. Miralcampo, 7, Pol. Ind. 
Miralcampo 
19200 Azuqueca de Henares (Guadalajara) 
Spain </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Teva Pharma Belgium N.V./S.A./AG 
T l/Tel: +32 38207Lietuva 
UAB Teva Baltics 
Tel: +370 52660  </p>
<p>Te : +359 24899Luxembourg/Luxemburg 
Teva Pharma Belgium N.V./S.A./AG 
Belgique/Belgien 
T l/Tel: +32 38207 esk  republika 
Teva Pharmaceuticals CR, s.r.o. 
Tel: +420 251007Magyarorsz g 
Teva Gy gyszergy r Zrt. 
Tel: +36 12886Danmark 
Teva Denmark A/S 
Tlf: +45 44985Malta 
Teva Pharmaceuticals Ireland 
L-Irlanda 
Tel: +44 2075407Deutschland 
TEVA GmbH<br />
Tel: +49 73140Nederland 
Teva Nederland B.V. 
Tel: +31 8000228Eesti 
UAB Teva Baltics Eesti filiaal 
Tel: +372 6610Norge 
Teva Norway AS 
Tlf: +47 66775<br />
TEVA HELLAS  . . 
 : +30 2118805 sterreich 
ratiopharm Arzneimittel Vertriebs-GmbH 
Tel: +43 1970Espa a 
Teva Pharma, S.L.U. 
Tel: +34 913873Polska 
Teva Pharmaceuticals Polska Sp. z o.o. 
Tel: +48 223459France 
Teva Sant<br />
T l: +33 155917Portugal 
Teva Pharma - Produtos Farmac uticos, Lda. 
Tel: +351 214767Hrvatska 
Pliva Hrvatska d.o.o. 
Tel: +385 13720Rom nia 
Teva Pharmaceuticals S.R.L. 
Tel: +40 212306Ireland 
Teva Pharmaceuticals Ireland 
Tel: +44 2075407Slovenija 
Pliva Ljubljana d.o.o. 
Tel: +386 15890 sland 
Teva Pharma Iceland ehf. 
S mi: +354 5503Slovensk  republika 
TEVA Pharmaceuticals Slovakia s.r.o. 
Tel: +421 257267Italia 
Teva Italia S.r.l 
Tel: +39 028917Suomi/Finland 
Teva Finland Oy 
Puh/Tel: +358 201805<br />
TEVA HELLAS  . . </p>
<p>: +30 2118805Sverige 
Teva Sweden AB 
Tel: +46 42121Latvija 
UAB Teva Baltics fili le Latvij<br />
Tel: +371 67323United Kingdom (Northern Ireland) 
Teva Pharmaceuticals Ireland 
Ireland 
Tel: +44 2075407This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-8fbc69d3de50a0eced9467159e7edfb2
InstanceOf: CompositionUvEpi
Title: "Composition for colobreathe Package Leaflet"
Description:  "Composition for colobreathe Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6f08bfaab2005a985ea433c3e1d4d35c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - colobreathe"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at bruge Colobreathe 
3. Sådan skal du bruge Colobreathe 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger  </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What colobreathe is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What colobreathe is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Colobreathe indeholder colistimethatnatrium, en type antibiotikum, der kaldes polymyxin. </p>
<p>Colobreathe bruges til at kontrollere vedvarende lungeinfektioner, som skyldes bakterien 
Pseudomonas aeruginosa hos voksne patienter og børn på 6 år og derover med cystisk fibrose. 
Pseudomonas aeruginosa er en meget almindelig bakterie, som næsten alle patienter med cystisk 
fibrose inficeres med på et tidspunkt i deres liv. Nogle personer vil få denne infektion, når de er meget 
unge, men for andre sker dette meget senere. Hvis denne infektion ikke kontrolleres hensigtsmæssigt, 
vil den forårsage skade på lungerne. </p>
<p>Sådan virker lægemidlet 
Colobreathe virker ved at ødelægge bakteriernes cellemembran, hvorved cellerne dør.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take colobreathe"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take colobreathe"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Colobreathe: </p>
<ul>
<li>hvis du eller dit barn er allergisk over for colistimethatnatrium, colistinsulfat eller polymyxiner. </li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du bruger Colobreathe. </p>
<p>Fortæl lægen, hvis du/dit barn nogensinde har haft nogen af følgende sygdomme </p>
<ul>
<li>
<p>Har reageret dårligt på inhaleret tørpulvermedicin tidligere, medmindre dette allerede er blevet 
diskuteret med din læge. </p>
</li>
<li>
<p>Har en muskellidelse kendt som myasthenia gravis eller den nedarvede lidelse porfyri. </p>
</li>
<li>
<p>Blod i opspyttet (det, som hostes op).  </p>
</li>
</ul>
<p>Efter hver inhalering af Colobreathe skal munden skylles med vand. Skyllevandet må ikke synkes.<br />
Ved at skylle munden kan du mindske risikoen for at udvikle en superinfektion med svamp i munden 
under behandlingen, ligesom du kan mindske den ubehagelige smag ved colistimethatnatrium. </p>
<p>Når du eller dit barn begynder at bruge Colobreathe, kan du eller dit barn få hoste, åndenød, følelse af 
stramhed om brystkassen eller hvæsen. Disse bivirkninger kan mindskes, når du fortsætter med at 
bruge inhalatoren, eller lægen kan ordinere en bronkodilatator, der skal bruges før eller efter brugen af 
Colobreathe. Hvis nogle af disse virkninger bliver et problem, skal du spørge din læge til råds, så 
han/hun kan ændre din behandling.  </p>
<p>Hvis du eller dit barn har problemer med nyrerne eller nervesystemet, skal der udvises forsigtighed 
ved brug af Colobreathe, og din læge skal være opmærksom på dette. </p>
<p>Hvis du eller dit barn skal have andre former for colistimethatnatrium via enten injektion eller 
forstøver, skal der udvises forsigtighed, og din læge skal være opmærksom på dette. </p>
<p>Børn 
Giv ikke Colobreathe til børn under 6 år, da det ikke er egnet til dem. </p>
<p>Brug af anden medicin sammen med Colobreathe </p>
<p>Fortæl det altid til lægen, hvis du eller dit barn bruger anden medicin, for nylig har brugt anden 
medicin eller planlægger at bruge anden medicin. Dette gælder også medicin, som ikke er købt på 
recept og navnlig: </p>
<ul>
<li>
<p>Hvis du eller dit barn får aminoglykosid-antibiotika, som anvendes til at behandle infektioner, 
skal der udvises forsigtighed.  </p>
</li>
<li>
<p>Hvis du eller dit barn lider af myasthenia gravis og tager antibiotika af macrolid-typen, såsom 
azithromycin og clarithromycin, eller fluoroquinoloner, såsom norfloxacin og ciprofloxacin. 
Hvis denne medicin tages samtidigt med Colobreathe, kan det give problemer med 
muskelsvækkelse. </p>
</li>
<li>
<p>Hvis du eller dit barn får colistimethatnatrium via injektion eller forstøver, skal der udvises 
forsigtighed. </p>
</li>
<li>
<p>Hvis du eller dit barn skal helbedøves, skal der udvises forsigtighed. </p>
</li>
</ul>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du bruger dette lægemiddel. </p>
<p>Der er ingen eller utilstrækkelig information om sikkerheden ved anvendelse af Colobreathe til 
gravide kvinder. Din læge bør rådgive dig om, hvorvidt fordelene ved at bruge medicinen overstiger 
risiciene, før du bruger Colobreathe. </p>
<p>Absorberet colistimethatnatrium kan udskilles i mælk. Du skal tale med din læge om brugen af 
Colobreathe. </p>
<p>Trafik- og arbejdssikkerhed 
Det er muligt, at du, mens du bruger Colobreathe, oplever svimmelhed, forvirring eller får problemer 
med dit syn. Du må ikke føre motorkøretøjer eller bruge maskiner, før symptomerne er forsvundet. </p>
<p>Colobreathe indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. kapsel, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take colobreathe"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take colobreathe"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug altid lægemidlet nøjagtigt efter lægens anvisning. Er du/dit barn i tvivl, så spørg lægen. </p>
<p>Den første dosis bør gives under lægelig overvågning. </p>
<p>Den anbefalede dosis er </p>
<p>Voksne og børn på 6 år eller derover </p>
<ul>
<li>
<p>Indholdet i en Colobreathe-kapsel bør inhaleres to gange om dagen ved anvendelse af 
Turbospin-inhalatoren. </p>
</li>
<li>
<p>Der bør være 12 timer mellem doserne. </p>
</li>
</ul>
<p>Rækkefølge for andre behandlinger, som skal tages eller udføres </p>
<p>Hvis du/dit barn bruger andre behandlinger for cystisk fibrose, skal du eller dit barn bruge dem i den 
følgende rækkefølge: </p>
<ul>
<li>
<p>Inhalations-bronkodilatorer </p>
</li>
<li>
<p>Lungefysioterapi </p>
</li>
<li>
<p>Andre lægemidler til inhalation </p>
</li>
<li>
<p>Derefter Colobreathe </p>
</li>
</ul>
<p>Du/dit barn skal fastlægge rækkefølgen af behandlingerne sammen med lægen. </p>
<p>Administration </p>
<p>Colobreathe inhaleres til lungerne, som et pulver fra kapslen, ved at bruge den håndholdte inhalator, 
som kaldes Turbospin. Colobreathe kan kun indgives ved anvendelse af denne enhed.  </p>
<p>Colobreathe-kapslerne må ikke sluges. </p>
<p>For at inhalere Colobreathe fra kapslen gennem Turbospin-inhalatoren skal du følge den 
fremgangsmåde, der beskrives nedenfor. Din læge, apotekspersonalet eller sygeplejersken bør vise 
dig/dit barn, hvordan medicinen skal inhaleres, når du eller dit barn starter på behandlingen:  </p>
<p>Klemme </p>
<p>Hætte </p>
<p>Mundstykke </p>
<p>Luftsprækker </p>
<p>Pulveriseringskammer </p>
<p>Greb </p>
<p>Stempel </p>
<p>Turbospin inhalator 
Sådan tager du Colobreathe ved hjælp af Turbospin-inhalatoren </p>
<p>Sådan forbereder du Turbospin </p>
<ol>
<li>
<p>Fjern hætten. Du skal blot trække let i den. </p>
</li>
<li>
<p>Skru mundstykket af, så du kan se kamret i Turbospin-inhalatoren. </p>
</li>
<li>
<p>Tag én kapsel ud af blisterpakningen. Når du har taget kapslen ud, skal den bruges med det 
samme. </p>
</li>
<li>
<p>Sæt forsigtigt kapslen ind i kamret med den bredeste ende først. Det er ikke nødvendigt at bruge 
kræfter. </p>
</li>
<li>
<p>Sæt nu mundstykket tilbage på plads ved at skrue det på. </p>
</li>
</ol>
<p>Gennemboring af kapslen og inhalering af medicinen </p>
<ol>
<li>
<p>Sådan gennembores kapslen: 
• Hold inhalatoren med mundstykket opad og skub forsigtigt stemplet opad, indtil den synlige 
linje nås. Du vil kunne mærke modstand, og det betyder, at kapslen er låst fast og klar til 
gennemboring. Hold denne position, inden du fortsætter med at udføre gennemboringen. 
• Fortsæt nu med at skubbe stemplet så langt som muligt, mens kapslen er låst fast, og slip 
derefter. </p>
</li>
<li>
<p>Kapslen er herefter gennemboret, og indholdet kan inhaleres. 
• Gennembor ikke kapslen mere end én gang. Du kan måske se en pulversky komme ud af 
kammeret, når kapslen gennembores. Dette er normalt. </p>
</li>
<li>
<p>Ånd langsomt ud. Placér derefter mundstykket mellem læberne og tænderne. Sørg for, at dine 
læber slutter tæt om mundstykket. Pas på, at du ikke dækker luftsprækkerne med dine fingre under 
inhalation. </p>
</li>
<li>Træk derefter vejret langsomt og dybt gennem munden i et tempo, så du kan høre eller mærke 
kapslen snurre rundt.   </li>
<li>Fjern Turbospin-inhalatoren fra munden og hold vejret i ca. 10 sekunder, eller så længe det er 
behageligt; ånd derefter langsomt ud. </li>
<li>Hvis du ikke kan høre kapslen snurre rundt, kan det være, at kapslen sidder fast i kamret.  Hvis 
dette sker, kan du løsne kapslen ved forsigtigt at banke på inhalatorens kammer. Du må ikke prøve 
at løsne kapslen ved at trykke på stemplet gentagne gange.  Hvis kapslen ikke kan løsnes, og 
pulveret ikke kan inhaleres, skal du smide den ødelagte kapsel, inklusive eventuelt tilbageværende 
pulver, ud, og bruge en anden. </li>
<li>Inhalér medicinen igen ved at gentage trin 7-8, så du er sikker på, at kapslen er tømt. </li>
<li>Du kan kontrollere, om kapslen er tom ved at skrue mundstykket af og tjekke kapslen. Hvis den 
ikke er tom, skal du gentage trin 7, 8 og 9, indtil du har inhaleret alt indholdet. </li>
<li>Når alt indholdet er inhaleret, skal du skylle din mund grundigt med vand og spytte vandet ud 
igen. </li>
</ol>
<p>Sådan fjerner du den tomme kapsel fra Turbospin </p>
<ol>
<li>Når kapslen er tom, skruer du mundstykket af og fjerner og bortskaffer den tomme kapsel. </li>
</ol>
<p>Yderligere oplysninger  </p>
<p>Når du trækker vejret langsomt, suger du luft gennem Turbospin-inhalatorens krop og ind i kamret 
med kapslen. De bittesmå partikler med medicin i kapslen hvirvles op af luftstrømmen og flyver ned 
gennem dine luftveje til lungerne. </p>
<p>Indimellem kan meget små stykker af kapslens skal komme ind i munden eller luftvejene.  </p>
<ul>
<li>
<p>Hvis dette sker, kan du mærke dem på tungen eller i luftvejene.  </p>
</li>
<li>
<p>Skallen er lavet af gelatine, som er harmløs for mennesker, hvis den synkes eller inhaleres. </p>
</li>
<li>
<p>Risikoen for, at kapslen går i stykker, er større, hvis kapslen gennembores mere end én gang i trin </p>
</li>
<li>Rengøring af Turbospin-inhalatoren. </li>
</ul>
<p>Turbospin-inhalatoren skal rengøres efter hver dosis ved at følge nedenstående fremgangsmåde: 
1. Tryk stemplet helt i bund et par gange, mens du holder kammeret på hovedet. 
2. Rengør kammeret ved at bruge en klud eller en tot vat. Du må ikke bruge vand. 
3. Skru mundstykket stramt på plads, sæt hætten på, og inhalatoren er nu klar til at blive brugt til 
din næste dosis. </p>
<p>Hvis du/dit barn har brugt for meget Colobreathe eller ved et uheld har slugt kapslen, skal du 
straks kontakte din læge. </p>
<p>Hvis du/dit barn har glemt at bruge Colobreathe. </p>
<p>Hvis du/dit barn har glemt at tage en dosis Colobreathe, så skal du/dit barn tage den glemte dosis, så 
snart du/dit barn kommer i tanke om det. Du/dit barn må ikke tage 2 doser inden for 12 timer. Derefter 
fortsættes som instrueret. </p>
<p>Hvis du/dit barn holder op med at bruge Colobreathe. </p>
<p>Stop ikke behandlingen, medmindre lægen siger, at du/dit barn skal. Lægen vil beslutte, hvor længe 
din/dit barns behandling skal fortsætte. </p>
<p>Spørg lægen, hvis der er noget, du/dit barn er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Allergiske reaktioner </p>
<p>Det er muligt, at der kan forekomme en allergisk reaktion, når du bruger Colobreathe (typisk kan 
alvorlige allergiske reaktioner forårsage udslæt, opsvulmning af ansigtet, tungen og halsen, gøre det 
umuligt at trække vejret på grund af forsnævring af luftvejene og bevidstløshed). Hvis du/dit barn 
oplever tegn på en allergisk reaktion, skal du straks søge læge. </p>
<p>Andre bivirkninger </p>
<p>Du/dit barn kan få en ubehagelig smag i munden efter inhalation af Colobreathe.  </p>
<p>Meget almindelige bivirkninger (kan forekomme hos mere end 1 ud af 10 behandlede): </p>
<ul>
<li>
<p>Vejrtrækningsbesvær </p>
</li>
<li>
<p>Hoste, halsirritation </p>
</li>
<li>
<p>Hæs eller svag eller endda mistet stemme </p>
</li>
<li>
<p>Ubehagelig smag </p>
</li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos 1 ud af 10 behandlede): </p>
<ul>
<li>
<p>Hovedpine </p>
</li>
<li>
<p>Ringen eller brummen for øret, balanceproblemer </p>
</li>
<li>
<p>Ophostning af blod, hvæsen, brystubehag, astma, produktiv hoste (en hoste som frembringer 
slim), lungeinfektion, knitrende lyd i lungerne (din læge vil kunne høre dette, når han/hun lytter 
til dine lunger med et stetoskop) </p>
</li>
<li>
<p>Opkastning, kvalme  </p>
</li>
<li>
<p>Ændringer af din lungefunktion (konstateres ved en test) </p>
</li>
<li>
<p>Ledsmerter </p>
</li>
<li>
<p>Mangel på energi, træthed </p>
</li>
<li>
<p>Forhøjet temperatur </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos 1 ud af 100 behandlede): </p>
<ul>
<li>
<p>Allergiske (overfølsomheds-) reaktioner, tegnene kan omfatte udslæt og kløe </p>
</li>
<li>
<p>Vægtudsving, nedsat appetit  </p>
</li>
<li>
<p>Angst </p>
</li>
<li>
<p>Anfald </p>
</li>
<li>
<p>Søvnighed </p>
</li>
<li>
<p>Tilstopning af ørerne </p>
</li>
<li>
<p>Brystsmerter </p>
</li>
<li>
<p>Stakåndethed </p>
</li>
<li>
<p>Næseblod, katar (slim i din næse, som kan få dig til at føle, at din næse er stoppet), ophostning 
af tykt, grønt slim, smerter i halsen og bihulerne) </p>
</li>
<li>
<p>Usædvanlige lyde i brystet (din læge kan høre dette ved at lytte til dine lunger med et stetoskop) </p>
</li>
<li>
<p>Diarré, luft i maven  </p>
</li>
<li>
<p>Overdreven produktion af spyt </p>
</li>
<li>
<p>Tandpine </p>
</li>
<li>
<p>Protein i urinen (konstateres ved en test) </p>
</li>
<li>
<p>Tørst </p>
</li>
</ul>
<p>De ovennævnte bivirkninger er blevet set med samme hyppighed hos personer i alle aldre. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>
<p>Tal med lægen eller apotekspersonalet, hvis du/dit barn får en bivirkning. Det gælder også 
bivirkninger, der ikke er nævnt her. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store colobreathe"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store colobreathe"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og på blisteren efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Colobreathe må ikke opbevares ved temperaturer over 25 °C. 
Opbevares i den originale yderpakning indtil umiddelbart før anvendelse for at beskytte mod fugt.  </p>
<p>Hvis du/dit barn ved et uheld fjerner folien, og nogle kapsler bliver frit tilgængelige, skal disse kapsler 
kasseres. </p>
<p>Bortskaf Turbospin-inhalatoren, når hele behandlingspakken er brugt. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Colobreathe indeholder: </p>
<p>Aktivt stof: colistimethatnatrium. Hver kapsel indeholder 1.662.500 IE, (hvilket svarer til ca. 125 mg) 
colistimethatnatrium. </p>
<p>Øvrige indholdsstoffer: 
Kapselskal 
Gelatine 
Polyethylenglycol 
Natriumlaurilsulfat 
Renset vand </p>
<p>Udseende og pakningsstørrelser </p>
<p>Colobreathe inhalationspulver i kapsler (inhalationspulver) leveres som små, hårde, transparente 
gelatinekapsler, der indeholder et fint, hvidt pulver.  </p>
<p>Turbospin er en pulverinhalator drevet af det inspiratoriske flow og fremstillet af polypropylen og 
rustfrit stål. </p>
<p>Kapslerne er pakket i blisterpakninger, som ligger i æsker med: </p>
<p>• 56 hårde kapsler og én Turbospin-inhalator, hvilket er nok til 4 ugers brug. 
• 8 hårde kapsler og én Turbospin-inhalator, hvilket er nok til 4 dages brug. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>Essential Pharma Limited, 
Vision Exchange Building, 
Triq it-Territorjals, Zone 1, 
Central Business District, 
Birkirkara, CBD 1070, Malta </p>
<p>Fremstiller </p>
<p>Teva Pharmaceuticals Europe BV 
Swensweg 5 
2031 GA Haarlem 
Holland </p>
<p>Millmount Healthcare Limited 
Block 7, City North Business Campus 
Stamullen 
Co Meath 
K32 YDIrland </p>
<p>Merckle GmbH 
Ludwig-Merckle-Str-3 
89143 Blaubeuren 
Tyskland </p>
<p>Laboratorios Liconsa, S.A. 
Avda. Miralcampo, 7, Pol. Ind. 
Miralcampo 
19200 Azuqueca de Henares (Guadalajara) 
Spanien </p>
<p>Denne indlægsseddel blev senest ændret 02/2 </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-8fbc69d3de50a0eced9467159e7edfb2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for colobreathe Package Leaflet for language en"
Description: "ePI document Bundle for colobreathe Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-8fbc69d3de50a0eced9467159e7edfb2"
* entry[0].resource = composition-en-8fbc69d3de50a0eced9467159e7edfb2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8fbc69d3de50a0eced9467159e7edfb2"
* entry[=].resource = mp8fbc69d3de50a0eced9467159e7edfb2
                            
                    
Instance: bundlepackageleaflet-da-8fbc69d3de50a0eced9467159e7edfb2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for colobreathe Package Leaflet for language da"
Description: "ePI document Bundle for colobreathe Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-8fbc69d3de50a0eced9467159e7edfb2"
* entry[0].resource = composition-da-8fbc69d3de50a0eced9467159e7edfb2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8fbc69d3de50a0eced9467159e7edfb2"
* entry[=].resource = mp8fbc69d3de50a0eced9467159e7edfb2
                            
                    



Instance: mp8fbc69d3de50a0eced9467159e7edfb2
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product colobreathe"
Description: "colobreathe"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/11/747/001 56 hard capsules (4 blisters of 14 capsules)"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Colobreathe is indicated for the management of chronic pulmonary infections due to Pseudomonas"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "colobreathe"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 8fbc69d3de50a0eced9467159e7edfb2ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "colobreathe"

* status = #current
* mode = #working

* title = "List of all ePIs associated with colobreathe"

* subject = Reference(mp6f08bfaab2005a985ea433c3e1d4d35c)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#colobreathe "colobreathe"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-8fbc69d3de50a0eced9467159e7edfb2) // colobreathe en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-8fbc69d3de50a0eced9467159e7edfb2) // colobreathe da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-8fbc69d3de50a0eced9467159e7edfb2
InstanceOf: List

* insert 8fbc69d3de50a0eced9467159e7edfb2ListRuleset
    